The Institute focusses on “bench to bedside” translational research to develop vaccinations, gene therapy and cell therapy to target immune-related conditions, as well as new types of transplant. Clinical areas include:
- cancer and leukaemia
- chronic infections such as HIV, viral hepatitis and tuberculosis
- auto-immune diseases including diabetes, scleroderma and inflammatory bowel disease
- inherited immunodeficiency
- other rare diseases such as haemophilia and amyloidosis
- tissue and organ transplantation.
Specific projects to improve early diagnosis and therapeutic options include:
- Successful development of gene therapy for haemophilia B, and expanding this to other forms of haemophilia and to lysosomal storage diseases.
- Improviding leukaemia immunotherapy through new lentiviral-vector vaccines targetting skin dendritic cells.
- Developing new vaccination protocols to prevent viral disease in transplant patients
- Adoptive cell therapy for leukaemia/lymphoma and viral infection
- Innovative gene therapies for leukaemia, solid cancers and chronic infection
- Discovering the genetic basis of certain forms of immunodeficiency and autoimmune conditions such as inflammatory bowel disease, facilitating early diagnosis and treatment
- New biological therapies for patients with scleroderma, rheumatoid arthritis and pulmonary arterial hypertension
- Tissue engineering and artificial organs for transplantation
- Immune therapy for type 1 diabetes
- Immune regulation and transplantation immunity
- Hepatitis C virus cell-entry and antibody modulation.
Page last modified on 29 jul 13 15:33